Previous research has demonstrated an interaction between MDM2 and TP53 at the molecular level [52], and the combined effects of MDM2 SNP 309 and TP53 Arg72Pro have been examined in lung cancer, Li–Fraumeni syndrome and non-polyposis colorectal cancer, with conflicting results [53], [54], [55]. The gene discussed is TP53; the disease is lung carcinoma.